🇺🇸 FDA

Intelligence · Clinical Pipeline

Ningbo Cancer Hospital Pipeline

All ClinicalTrials.gov programs at Ningbo Cancer Hospital — phase, modality, and trial IDs.

Programs
120

Quick answer

Ningbo Cancer Hospital has 120 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  2. OXALIPLATIN, IRINOTECAN, Vectibix 20 mg/ml concentrate for solution for infusion, FOLINIC ACID, CALCIUM LEVOFOLINATE, FLUOROURACIL

    Ningbo Cancer Hospital

    RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method

    phase 2 small molecule active

    1 trial

  3. OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB

    Ningbo Cancer Hospital

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial

  4. PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  5. PF-07248144, FULVESTRANT ZENTIVA 250 mg, solution injectable en seringue préremplie, PF-07248144

    Ningbo Cancer Hospital

    Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting

    phase 2 small molecule active

    1 trial

  6. Pemazyre 4.5 mg tablets

    Ningbo Cancer Hospital

    Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rearrangement or activating mutation, outside of the approved indications for any selective FGFR inhibitor in France

    phase 2 small molecule active

    1 trial

  7. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Ningbo Cancer Hospital

    Clear Cell Renal Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  8. Precision Cells

    Ningbo Cancer Hospital

    Precision Cell Immunotherapy

    phase 2 mab active

    1 trial

  9. Revlimid 25 mg hard capsules, Isatuximab, Dexamethasone Tablets 2 mg, Revlimid 15 mg hard capsules, Isatuximab, VELCADE 1 mg powder for solution for injection, Revlimid 10 mg hard capsules

    Ningbo Cancer Hospital

    Newly diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  10. Stivarga 40 mg film-coated tablets

    Ningbo Cancer Hospital

    Bone sarcoma

    phase 2 small molecule active

    1 trial

  11. TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN

    Ningbo Cancer Hospital

    Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.

    phase 2 small molecule active

    1 trial

  12. TRASTUZUMAB, FULVESTRANT, EXEMESTANE, PERTUZUMAB, PERTUZUMAB, TRASTUZUMAB, PERTUZUMAB, TUKYSA 150 mg film-coated tablets, LETROZOLE, TUKYSA 50 mg film-coated tablets, TRASTUZUMAB, ANASTROZOLE

    Ningbo Cancer Hospital

    HER2+ metastatic breast cancer with isolated brain progression

    phase 2 small molecule active

    1 trial

  13. TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE

    Ningbo Cancer Hospital

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

  14. TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tablets

    Ningbo Cancer Hospital

    Non-resectable locally advanced or metastatic HER2-positive breast cancer

    phase 2 small molecule active

    1 trial

  15. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  16. Tecentriq 1,200 mg concentrate for solution for infusion, EXL01, IMFINZI 50 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  17. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial

  18. Verzenios 50 mg film-coated tablets

    Ningbo Cancer Hospital

    High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.

    phase 2 small molecule active

    1 trial

  19. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  20. Zejula 100 mg hard capsules, Zejula 100 mg film-coated tablets, JEMPERLI 500 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    metastatic or recurrent endometrial or ovarian carcinosarcoma

    phase 2 small molecule active

    1 trial

  21. Zelboraf 240 mg film-coated tablets

    Ningbo Cancer Hospital

    Patients with metastatic or unresectable locally advanced malignancies harboring BRAF genomic alterations, the biological target of vemurafenib, and who are no more amenable to curative treatment

    phase 2 small molecule active

    1 trial

  22. Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. (The CPD-DARA Study).

    Ningbo Cancer Hospital

    Relapsed/ refractory multiple myeloma

    phase 1 other active

    1 trial

  23. Lutrate Depot Trimestral 22,5 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 150 mg film-coated tablets, Femara 2.5 mg Tablets, Arimidex® 1 mg film-coated tablets, Zoladex 10,8 mg implantat, Aromasil 25 mg comprimidos recubiertos, Verzenios 100 mg film-coated tablets, Zoladex 3,6 mg implantat, Kisqali 200 mg film-coated tablets, Lutrate Depot Mensual 3,75 mg polvo y disolvente para suspensión inyectable de liberación prolongada, Verzenios 50 mg film-coated tablets

    Ningbo Cancer Hospital

    Early Breast Cancer

    approved small molecule active

    1 trial

  24. SomaKit TOC 40 micrograms kit for radiopharmaceutical preparation

    Ningbo Cancer Hospital

    Gastroenteropancreatic neuroendocrine tumors

    approved small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Ningbo Cancer Hospital have?

120 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.